Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S213010, C540S593000, C546S146000
Reexamination Certificate
active
07875631
ABSTRACT:
Compounds of the formula (I): where R2, R5, R6 have the meanings as given in the description, and U, V and W, respectively, may be CR2′, CR4′ and CR6′, respectively (with the definitions of R2′, R4′ and R6′ again as in the description), or may be N, were synthesized. They were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
REFERENCES:
patent: 4349472 (1982-09-01), Gold et al.
patent: 6337338 (2002-01-01), Kozlowski et al.
patent: 1 113 007 (2001-07-01), None
patent: WO 02/102804 (2002-12-01), None
patent: WO 02/102805 (2002-12-01), None
patent: WO 03/048133 (2003-06-01), None
patent: WO 03/100059 (2003-12-01), None
Carlos L. Arteaga et al., “Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against the Type I Somatomedin Receptor”,Cancer Res., vol. 49, pp. 6237-6241 (Nov. 15, 1989).
D. D. De Leon et al., “Effects of Insulin-Like Growth Factors (IGFs) and IGF Receptor Antibodies on the Proliferation of Human Breast Cancer Cells”,Growth Factors, vol. 6, pp. 327-336 (1992).
David W. Andrews et al., “Results of a Pilot Study Involving the Use of an Antisense Oligooxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrycytomas”,J. Clin. Onc., vol. 19, No. 8, pp. 2189-2200 (Apr. 15, 2001).
P.J. White et al., “Antisense Inhibition of IGF Receptor Expression in HaCaT Keratinocytes: A Model for Antisense Strategies in Keratinocytes”,Antisense&Nuc. Acid Drug Dev., vol. 10, pp. 195-203 (2000).
Diane Prager et al., “Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant”,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 2181-2185 (Mar. 1994).
Krysztof Reiss et al., “Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-Like Growth Factor I Receptor with a Bystander Effect”,Clin. Cancer Res., vol. 4, pp. 2647-2655 (Nov. 1998).
Laura K. Shawver et al., “Receptor Tyrosine kinases as targets for inhibition of angiogenesis”,DDT, vol. 2, No. 2, (Feb. 1997).
Jane Pritchard et al., “Synovial Fibroblasts from Patients with Rheumatoid Arthritis, Like Fibroblasts from Graves' Disease, Express High Levels of IL-16 When Treated with Igs against Insulin-Like Growth Factor-1 Receptor”,J. lmmun., pp. 3564-3569 (2004).
A.J. Salisbury et al., “Development of Molecular Agents for IGF Receptor Targeting”,Horm. Metab. Res., vol. 35, pp. 843-849 (2003).
Constantine S. Mitsiades et al., “Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors”,Cancer Cell, vol. 5, pp. 221-230 (Mar. 2004).
Ji Sun Lee et al., “Synthesis of 1,2,3,4-Tetrahydroisoquinoline-2-sulfonic Acids,”Bull Korean Chem. Soc., vol. 24, No. 7, pp. 1041-1044 (2003).
T.E. Adams et al., “Structure and function of the type 1 insulin-like growth factor receptor,”CMLS Cell Mol. Life Sci., vol. 57, pp. 1050-1093 (2000).
Renato Baserga et al., “The IFG-I receptor in cell growth, transformation and apoptosis,”Biochimica et Biophysica Acta, vol. 1332, pp. F105-F126 (1997).
Thea Kalebic et al., “In Vivo Treatment with Antibody against IFG-1 Receptor Suppresses Growth of Human Rhabdomyosarcoma and Down-Regulates p34cdc2,”Cancer Research, vol. 54, pp. 5531-5534 (Nov. 1, 1994).
Mariana Resnicoff et al., “Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor-1 (IGF-1) Receptor Are Nontumorigenic and Induce Regression of Wild-Type Tumors,”Cancer Research, vol. 54, pp. 2218-2222 (Apr. 15, 1994).
Consuelo D'Ambrosio et al., “A Soluble Insulin-like Growth Factor I Receptor That Induces Apoptosis of Tumor Cells in Vivo and Inhibits Tumorigenesis,”Cancer Research, vol. 56, pp. 4013-4020 (Sep. 1, 1996).
Frauke Rininsland et al., “Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells,”Proc. Natl. Acad. Sci. USA, vol. 94, pp. 5854-5859 (May 1997).
Keiichiro Nakamura et al., “Down-Regulation fo the Insulin-like Growth Factor I Receptor by Antisense RNA Can Reverse the Transformed Phenotype of Human Cervical Cancer Cell Lines,”Cancer Research, vol. 60, pp. 760-765 (Feb. 1, 2000).
Christopher J. Wraight et al., “Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides,”Nature Biotechnology, vol. 18, pp. 521-526 (May 2000).
Antoni Bayes-Genis et al., “The Insulin-Like Growth Factor Axis a Review of Atherosclerosis and Restenosis,”Circulation Research, pp. 125-130 (Feb. 4, 2000).
Li Long et al., “Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor Receptor,”Cancer Research, vol. 55, pp. 1006-1009 (Mar. 1, 1995).
Renato Baserga, “Controlling IGF-receptor function: a possible strategy for tumor therapy,”BTECH, vol. 14, pp. 150-152 (1996).
Renato Baserga et al., “The IGF-I Receptor and Cancer,”Endocrine, vol. 7, No. 1, pp. 99-102 (Aug. 1997).
V.M. Macauley et al., “Downregulation fo the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity tivity and impaired activation of Atm kinase,”Oncogene, vol. 20, pp. 4029-4040 (2001).
Marcelina Parrizas et al., Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins,Endocrinology, vol. 138, No. 4, pp. 1427-1433 (1997).
Galia Blum et al., “Substrate Competitive Inhibitors of IGF-I Receptor Kinase,”Biochemistry, vol. 39, No. 51, pp. 15705-15712 (2000).
Galia Blum et al., “Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics,”J. Biological Chemistry, vol. 278, No. 42, pp. 40442-40454 (Oct. 17, 2003).
Lena Kanter-Lewensohn et al., “Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway,”Molecular and Cellular Endocrinology, vol. 165, pp. 131-137 (2000).
Akira Akahori et al., “Cytotoxic Agents ofThujopsis dolabrata(L. fil.) Sieb et Zucc.”Chem. Pharm. Bull., vol. 20, No. 6, pp. 1150-1155 (1972).
Masahiko Kohno et al., “Synthesis of Phenethylamines by Hydrogenation of β-Nitrostyrenes,”Chem. Soc. of Japan, vol. 63, No. 4, pp. 1252-1254 (1990).
Stephen A DiBiase et al., “Direct Synthesis of α,β-Unsaturated Nitriles from Acetonitrile and Carbonyl Compounds: Survey, Crown Effects, and Experimental Conditions,”J. Org. Chem, vol. 44, No. 25, pp. 4640-4649 (1979).
Melvin Euerby et al., “A Convenient Synthesis of 3-Methylthiobenzaldehyde,”Synthetic Communications, vol. 11, No. 10, pp. 849-851 (1981).
Makoto Ando et al., “Catalytic Activities of Salicylaldehyde Derivatives, VI.1) Syntheses of Some Dimethylsulfionio Derivatives of Salicylaldehyde,”Bull. of the Chem. Soc. of Japan, vol. 51, No. 8, pp. 2435-2436 (1978).
Michael J. Munchhof et al., “A Novel Route to Chiral, Nonracemic 1-Alkyl- and 1-Aryl-Substituted Tetrahydroisoquinolines. Synthesis of (−)Salsolidine and (+)-Cryptostyline II,”J. Org. Chem., vol. 60, pp. 7086-7087 (1995).
Richard P. Polniaszek et a., “Stereoselective Reductions of Chiral Iminium Ions,”Tetrahedron Letters, vol. 28, No. 39, pp. 4511-4514 (1997).
Nobuyuki Uematsu et al., “Asymmetric Transfer Hydrogenation of lmines,”J. Am. Chem. Soc., vol. 118, pp. 4916-4917, (1996).
Gerrit J. Meuzelaar et al., “Chemistry of Opium Alkaloids, 451img id="CUSTOM-CHARACTER-00001" h
Gunzinger Jan
Leander Kurt
Analytecon S.A.
Davis Zinna N
Harness & Dickey & Pierce P.L.C.
LandOfFree
Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621094